Pruritus Clinical Trial
Official title:
Master Protocol of Two Randomized, Double Blind, Placebo-controlled, Multi-center, Parallel Group Studies to Evaluate the Efficacy and Safety of Dupilumab in Adult Patients With Chronic Pruritus of Unknown Origin (CPUO)
The main objective of the study is to assess efficacy and safety of dupilumab given up to 24 weeks in adults with CPUO. This is a master protocol which includes 2 parallel-treatment, double-blind, 2- arm Phase 3 staggered studies of similar design (Study A and Study B) in male and female participants aged 18 to 90 years with CPUO. Study B design may be adapted based on the results of Study A. For both Study A and B, after an up-to-4-week screening period, participants with severe pruritus (worst-itch numerical rating scale [WI-NRS ≥7) will enter a 4-week run-in period during with a non-sedative antihistamine and an emollient (moisturizer). Participants with severe pruritus (WI-NRS ≥7) at baseline will be randomized (1:1) to be treated for 24 weeks (Study A) or 12 weeks (Study B) with either dupilumab or matching placebo in addition to their antihistamine and emollient regimen. The treatment period for both study A and B will be followed by a 12-week follow-up period.
Study duration per participant will be up to 44 weeks (Study A) and 32 weeks (Study B). ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT05038982 -
Efficacy of Abrocitinib for Reducing Pruritus in Adults With Prurigo Nodularis and Chronic Pruritus of Unknown Origin
|
Phase 2 | |
| Completed |
NCT04510090 -
Evaluate the Safety, Tolerability, and PK of EP547 in Healthy Subjects and Subjects With Cholestatic or Uremic Pruritus
|
Phase 1 | |
| Terminated |
NCT01825655 -
Study of Using Long Acting Antihistamine to Treat Opioid Induced Itching
|
Phase 4 | |
| Completed |
NCT02143973 -
Open Label Extension Study of Nalbuphine HCl ER in Hemodialysis Patients With Uremic Pruritus
|
Phase 2/Phase 3 | |
| Completed |
NCT01236859 -
Gabapentin for Prophylaxis Intrathecal Morphine-Induced Pruritus
|
N/A | |
| Completed |
NCT00782054 -
Evaluation of Post Burn Rehabilitation Population for Itch Control
|
Phase 4 | |
| Completed |
NCT04999787 -
A Clinical Trial Evaluating the Efficacy, Safety, and Pharmacokinetics of HSK21542 Injection in Liver Disease Subjects With Pruritus
|
Phase 2 | |
| Recruiting |
NCT04256759 -
Dupilumab for the Treatment of Moderate to Severe Chronic Hepatic Pruritus
|
Phase 2 | |
| Completed |
NCT04337073 -
The Effect of Propofol on Dexamethasone-induced Perineal Pruritus
|
Early Phase 1 | |
| Completed |
NCT04415034 -
Scalp Pruritus Measurement Using Visual Analog Scale and 5-d Itch Scale in Children With Pediculosis Capitis
|
||
| Active, not recruiting |
NCT05525520 -
Study to Evaluate EP547 in Subjects With Cholestatic Pruritus Due to Primary Biliary Cholangitis or Primary Sclerosing Cholangitis
|
Phase 2 | |
| Recruiting |
NCT03340155 -
Mechanisms of Action of Photo(Chemo)Therapy in Skin Diseases
|
N/A | |
| Completed |
NCT04399525 -
Influence of H1-antihistamines on the Dermal Blood Flow Response to Histamine, Cinnamaldehyde and Capsaicin.
|
N/A | |
| Recruiting |
NCT02432508 -
Efficacy of Laser Acupuncture on Pruritus in Patients With Chronic Kidney Disease Undergoing Hemodialysis
|
N/A | |
| Completed |
NCT02653703 -
L-menthol as a Topical Counter-irritant to TRPA1-induced Neurogenic Inflammation and Pain
|
N/A | |
| Completed |
NCT01963793 -
Topical Aprepitant in Prurigo Patients
|
Phase 2 | |
| Completed |
NCT01232985 -
Efficacy and Tolerability Study of Device, RD047-26 for the Treatment of Mild to Moderate Atopic Dermatitis in Adults
|
Phase 2 | |
| Not yet recruiting |
NCT00577967 -
Gabapentin - A Solution to Uremic Pruritus?
|
N/A | |
| Recruiting |
NCT06120907 -
Swiss Itch Registry
|
||
| Recruiting |
NCT04589429 -
Adding Nalbuphine for Control of Intrathecal Morphine Pruritus
|
Phase 2 |